BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 20398393)

  • 1. A comparability study of 5 commercial KRAS tests.
    Oliner K; Juan T; Suggs S; Wolf M; Sarosi I; Freeman DJ; Gyuris T; Baron W; Bakker A; Parker A; Patterson SD
    Diagn Pathol; 2010 Apr; 5():23. PubMed ID: 20398393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories.
    Feigelson HS; Goddard KA; Johnson MA; Funk KC; Rahm AK; Kauffman TL; Chitale DA; Le Marchand L; Richards CS
    BMC Res Notes; 2012 Apr; 5():196. PubMed ID: 22534075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice.
    Sundström M; Edlund K; Lindell M; Glimelius B; Birgisson H; Micke P; Botling J
    BMC Cancer; 2010 Dec; 10():660. PubMed ID: 21122130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma.
    Lee S; Brophy VH; Cao J; Velez M; Hoeppner C; Soviero S; Lawrence HJ
    Virchows Arch; 2012 Feb; 460(2):141-9. PubMed ID: 22173329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells.
    Lewandowska MA; Jóźwicki W; Żurawski B
    Mol Diagn Ther; 2013 Jun; 17(3):193-203. PubMed ID: 23606169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High sensitivity of reverse-hybridization methodology in the detection of KRAS mutations from formalin-fixed paraffin-embedded colorectal cancer samples.
    De Miglio MR; Mura A; Uras MG; Manca A; Contini M; Murgia L; Zinellu A; Sotgia S; Carru C; Massarelli G; Cossu-Rocca P
    Diagn Mol Pathol; 2010 Dec; 19(4):201-8. PubMed ID: 21052001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of KRAS codon 12 and 13 mutations by mutant-enriched PCR assay.
    Chang YS; Er TK; Lu HC; Yeh KT; Chang JG
    Clin Chim Acta; 2014 Sep; 436():169-75. PubMed ID: 24863805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas.
    Harlé A; Busser B; Rouyer M; Harter V; Genin P; Leroux A; Merlin JL
    Virchows Arch; 2013 Mar; 462(3):329-35. PubMed ID: 23400679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
    Zhang X; Wang Y; Gao N; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of evaluation of DNA amplificability in KRAS mutation testing with dideoxy sequencing using formalin-fixed and paraffin-embedded colorectal cancer tissues.
    Okayama N; Nishioka M; Hazama S; Sakai K; Suehiro Y; Maekawa M; Sakamoto J; Iwamoto S; Kato T; Mishima H; Oka M; Hinoda Y
    Jpn J Clin Oncol; 2011 Feb; 41(2):165-71. PubMed ID: 20926413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of KRAS new predictive marker in a clinical laboratory.
    Bando I; Cillero L; Sanz-Ortega J; Llovet P; Pescador P; Ferrer M; de la Hoya M; Sastre J; García ED; Caldés T
    Clin Transl Oncol; 2012 Dec; 14(12):937-42. PubMed ID: 22865324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: Comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue.
    Kwon MJ; Lee SE; Kang SY; Choi YL
    Pathol Res Pract; 2011 Dec; 207(12):762-8. PubMed ID: 22070922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS testing in clinical laboratory: optimizing targeted therapy.
    Miravalle L; Lefferts JA; Al-Haddad M; Tsongalis GJ; Cheng L
    Cancer Genomics Proteomics; 2012; 9(5):337-41. PubMed ID: 22990113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls.
    Lamy A; Blanchard F; Le Pessot F; Sesboüé R; Di Fiore F; Bossut J; Fiant E; Frébourg T; Sabourin JC
    Mod Pathol; 2011 Aug; 24(8):1090-100. PubMed ID: 21516079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation analysis of BRAF exon 15 and KRAS codons 12 and 13 in Moroccan patients with colorectal cancer.
    Bennani B; Gilles S; Fina F; Nanni I; Ibrahimi SA; Riffi AA; Nejjari C; Benajeh DA; El Abkari M; Martin PM; Ouafik L
    Int J Biol Markers; 2010; 25(4):179-84. PubMed ID: 21161938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.
    Heideman DA; Lurkin I; Doeleman M; Smit EF; Verheul HM; Meijer GA; Snijders PJ; Thunnissen E; Zwarthoff EC
    J Mol Diagn; 2012; 14(3):247-55. PubMed ID: 22425762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct sequencing is a reliable assay with good clinical applicability for KRAS mutation testing in colorectal cancer.
    Wang J; Yang H; Shen Y; Wang S; Lin D; Ma L; Han X; Shi Y
    Cancer Biomark; 2013; 13(2):89-97. PubMed ID: 23838137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization.
    Ausch C; Buxhofer-Ausch V; Oberkanins C; Holzer B; Minai-Pour M; Jahn S; Dandachi N; Zeillinger R; Kriegshäuser G
    J Mol Diagn; 2009 Nov; 11(6):508-13. PubMed ID: 19797612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach.
    Carotenuto P; Roma C; Rachiglio AM; Tatangelo F; Pinto C; Ciardiello F; Nappi O; Iaffaioli RV; Botti G; Normanno N
    Pharmacogenomics; 2010 Aug; 11(8):1169-79. PubMed ID: 20712532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology.
    Perez K; Walsh R; Brilliant K; Noble L; Yakirevich E; Breese V; Jackson C; Chatterjee D; Pricolo V; Roth L; Shah N; Cataldo T; Safran H; Hixson D; Quesenberry P
    Exp Mol Pathol; 2013 Aug; 95(1):74-82. PubMed ID: 23528430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.